drugset / Trial / NCT02590094
Preoperative Bevacizumab and Ziv-Aflibercept Administration in PDR Subjects Undergoing PPV
RandomizedParallel-groupDouble-blindTreatment
Summary
To compare outcomes in subjects receiving different doses and treatment intervals of intravitreal bevacizumab or ziv-aflibercept preoperatively administered prior to undergoing vitrectomy for complications of proliferative diabetic retinopathy.
Timeline
- Start
- 2015-10
- Primary completion
- 2019-01-04
- Completion
- 2019-01-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Aflibercept | Protein / enzyme biologic | 1.25 mg | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 0.625 mg | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 1.25 mg | Other |
| Comparator | Bevacizumab | Monoclonal antibody | 2.5 mg | Other |